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Background
Inclusion of conserved regions of the HIV genome into
vaccine candidates may help to overcome problems of
global sequence diversity and could provide beneficial
effects by inducing T cell responses for which CTL escape
is likely associated with fitness costs.
Methods
We rationally designed an immunogen sequence consist-
ing of ''conserved elements'' (CE) that includes 7 seg-
ments of the Gag p24 protein. Responses to CE and to the
rest of p24 and the entire viral proteome were assessed in
HIV controllers (n = 15) and HIV non-controllers (n = 10)
using a comprehensive 18 mer overlapping peptide set
spanning the entire viral proteome and an 11 mer over-
lapping (by 10 residues) peptide set spanning Gag p24
and covering all CE and the most frequent occurring
mutations in this region.
Results
Controllers and non-controllers mounted comparable
number of responses to either entire p24 or CE only (8 vs.
7 for p24 and 3 in both groups for CE). Despite these fre-
quent reactivities in non-controllers, the contribution of
CE responses to total p24 magnitude was significantly
lower in non-controllers (p = 0.043). In addition, control-
lers showed a significantly higher recognition of variants,
both to the CE (median variant reactivity 3 vs 1, p = 0.01)
and total p24 (5 vs 2.5, p = 0.01), 44% of which were
responses to variants only, without reacting to the consen-
sus sequence. Importantly, the observed responses were
not driven by CTL activity to epitopes restricted by HLA
B27, HLA B57 or HLA B58, as such subjects were previ-
ously excluded.
Conclusion
Cross-reactive responses able to recognize CE epitope var-
iants present in controllers could possibly explain their
superior ability to control in vivo HIV replication. In addi-
tion, specific responses to subdominant sequence variants
that were not elicited by consensus sequences may repre-
sent more immunogenic viral sequences that could pro-
vide candidates for the induction of responses able to
protect from heterologous viral challenge.
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